Molecule is pioneering a platform that redefines how therapeutic research is funded and developed. By leveraging blockchain technology and tokenized intellectual properties (IPTs) and real-world assets (RWAs), Molecule connects scientists, investors, and patient communities to collaboratively accelerate the development of breakthrough therapies.

Molecule has funded and advanced 35+ research projects across longevity, neurology, oncology, immunology, cell and gene therapy, rare diseases, women’s health, and SynBio, with several programs progressing toward IND-enabling studies and clinical trials. These efforts generate tangible IP assets that integrate directly into the traditional biotech pipeline through a faster, more collaborative model.

To date, Molecule has mobilized $7.8M+ in direct research funding and helped catalyze an ecosystem valued at nearly $170M, enabling stakeholders to co-fund, co-own, and steward real-world biomedical assets across their development lifecycle.